Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide

Abstract

Analysis of data from the clinical trial CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) showed, that adding the values of other biochemical markers of cardiovascular risk, like apolipoprotein A-1, high-sensitive C-reactive protein (hsCRP), and N-terminal pro B-type natriuretic peptide (NT-proBNP) increases accuracy of an algoritmus for estimating cardiovascular risk.

Keywords

• Chronic heart failure
• rosuvastatin
• therapy
• cholesterol